ProLung, Inc., the leader in innovative predictive analytics technology and non-invasive tests for lung cancer, announced today the promotion of Aaron Stout to Chief Accounting Officer. Mr. Stout previously served as the Controller for ProLung.
ProLung, Inc., the leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today the promotion of Ryan Snow as the Director of Marketing and Business Development. Mr. Snow has been with the Company for three years and performed in multiple capacities, previously serving as the European Development Director.
ProLung, Inc., the leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today the successful closing of its private placement. The private offering was expected to raise $5.2 million and was oversubscribed by $3.0 million to a total of $8.2 million.
ProLung, Inc., a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer, announced today it has been selected to present at the upcoming Cavendish Global Health Impact Forum taking place May 7-9, 2017 in Washington, DC, co-hosted with the Virginia Biotechnology Association (VirginiaBio).
ProLung, a predictive analytics and risk stratification company that has developed a novel, cost effective, and non-invasive test to identify cancerous and noncancerous lung nodules, announced today that Robin L. Smith, MD, MBA, has joined the Company’s Board of Directors.
ProLung President and CEO Steven C. Eror warmly welcomes each of our valued shareholders to a happy and prosperous 2017.
Steven C. Eror, President and CEO of ProLung, meets with Gregory C. Simon, White House Cancer Moonshot Task Force, Executive Director in the Office of the Vice President.
San Francisco, California, Wednesday October 19, 2016
ProLungDX, a maker of lung cancer detection devices, is looking to raise USD 5.25m from high net worth investors for US commercial development in advance of an expected initial public offering or trade sale, according to CEO Steven Eror.
ProLungdx™ today announced plans to present its leading-edge innovation for patients at risk of lung cancer during the 2016 BIO Investor Forum in San Francisco, California October 18 and 19, 2016.
ProLungdx™ today announced plans to present its ground-breaking innovation for lung cancer patients at the AZBIO’s 2016 White Hat Life Science Investors Conference in Phoenix, Arizona September 21 and 22, 2016.
A major lung cancer screening trial, conducted by experts at the University of Liverpool, has found that patients with a high risk of developing lung cancer can be identified with early stage disease and have up to a 73% chance of surviving five years or more.
The Board of Directors of Fresh Medical Laboratories Inc., doing business as ProLungdx, today announced the appointment of Dr. John C. Ruckdeschel, M.D. to serve as a Director on the Company’s Board of Directors.
Fresh Medical Laboratories, Inc, doing business as ProLungdx™, announced today that its board has appointed Todd Morgan as Chairman of the Board of Directors.
Fresh Medical Laboratories, Inc., doing business as ProLungdx™, today announced the initial results of its ongoing European Lung Cancer Registry. When the Electro Pulmonary Nodule (EPN) Scan was administered to patients with lung nodules suspicious for cancer, the scan demonstrated results consistent with earlier research performed at Johns Hopkins and published in the Journal of Thoracic Oncology.